£0
The seed round was led by Meltwind and Start Codon to accelerate in vivo proof-of-concept studies.
"Incorporation of our technology into ADC products will accelerate and energise the important transition away from the 'one size fits all' approach currently being pursued in ADC development, resulting in novel products with a competitive and differentiated profile. The platform has the power to unlock the development of a new generation of powerful and well-tolerated drugs, which have been so far inaccessible to many cancer patients."
S
Spirea—Cambridge, UKMeltwind + 1 other

